New and Investigational Treatment Options for Dermatomycosis in the Era of Antifungal Resistance. [PDF]
Gupta AK, Liddy A, Wang T.
europepmc +1 more source
Osh2 mediates <i>Candida</i> species resistance to miltefosine by regulating zymosterol accumulation. [PDF]
Wu Y, Dai Y, Lu H, Jiang X, Wang Y.
europepmc +1 more source
Visceral Leishmaniasis in Southern Brazil: an overview of current epidemiology. [PDF]
Dambrós BP +5 more
europepmc +1 more source
Post-kala-azar dermal leishmaniasis: insights into underlying pathogenic mechanisms and genetic landscape. [PDF]
Mukherjee S +4 more
europepmc +1 more source
Prunus amygdalus var. amara seed extract enhances the antileishmanial activity of miltefosine. [PDF]
Akand SK +8 more
europepmc +1 more source
Off-label treatment with miltefosine for complex, pediatric Old World cutaneous leishmaniasis. [PDF]
Buchelt M +7 more
europepmc +1 more source
Immunomodulatory therapy of visceral leishmaniasis in HIV coinfected patients [PDF]
Adriaensen, Wim +5 more
core
Nucleoside Analogue with Thymidine Nucleobase Inhibits <i>Leishmania infantum</i> and Depolarizes the Plasma Membrane Potential In Vitro. [PDF]
Menezes C +5 more
europepmc +1 more source
Combination Therapy for the Treatment of Cutaneous Leishmaniasis Compared with Standard Drugs, <i>In Vitro</i> or <i>In Vivo</i>: A Systematic Review. [PDF]
Mousavi P +5 more
europepmc +1 more source
New Viability Assays for Acanthamoeba castellanii Trophozoites and Cysts Allow Rapid Assessment of Drug Activity. [PDF]
Flynn CA +4 more
europepmc +1 more source

